Scalable production of adeno-associated virus type 2 vectors via suspension transfection

被引:43
作者
Park, Joon Young [1 ]
Lim, Byung-Pil [1 ]
Lee, Kyuhyun [1 ]
Kim, Young-Gun [1 ]
Jo, Eui-Cheol [1 ]
机构
[1] MOGAM Biotechnol Res Inst, Yongin 449913, Kyonggi, South Korea
关键词
adeno-associated virus vectors; vector production; polyethylenimine (PEI); suspension transfection; bioreactor;
D O I
10.1002/bit.20776
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Vectors derived from adeno-associated virus type 2 (AAV2) are promising gene delivery vehicles, but it is still challenging to get the large number of recombinant adeno-associated virus (rAAV) particles required for large animal and clinical studies. Current transfection technology requires adherent cultures of HEK 293 cells that can only be expanded by preparing multiple culture plates. A single large-scale suspension culture could replace these multiple culture preparations, but there is currently no effective co-transfection scheme for generating rAAV from cells in suspension culture. Here, we weaned HEK 293 cells to suspension culture using hydrogel-coated six-well culture plates and established an efficient transfection strategy suitable for these cells. Then the cultures were gradually scaled up. We used linear polyethylenimine (PEI) to mediate transfection and obtained high transfection efficiencies ranging from 54% to 99%, thereby allowing efficient generation of rAAV vectors. Up to 10(13) rAAV particles and, more importantly, up to 10(11) infectious particles were generated from a 2-L bioreactor culture. The suspension-transfection strategy of this study facilitates the homogeneous preparation of rAAV at a large scale, and holds further potential as the basis for establishing a manufacturing process in a larger bioreactor. (c) 2006 Wiley Periodicals, Inc.
引用
收藏
页码:416 / 430
页数:15
相关论文
共 51 条
[41]   Serum-free production and column purification of adeno-associated virus type 5 [J].
Smith, RH ;
Ding, CT ;
Kotin, RM .
JOURNAL OF VIROLOGICAL METHODS, 2003, 114 (02) :115-124
[42]  
SNYDER O, 1996, CURRENT PROTOCOLS HU
[43]   Production of clinical-grade recombinant adeno-associated virus vectors [J].
Snyder, RO ;
Flotte, TR .
CURRENT OPINION IN BIOTECHNOLOGY, 2002, 13 (05) :418-423
[44]  
Snyder RO, 1999, J GENE MED, V1, P166
[45]   Insect cells as a factory to produce adeno-associated virus type 2 vectors [J].
Urabe, M ;
Ding, CT ;
Kotin, RM .
HUMAN GENE THERAPY, 2002, 13 (16) :1935-1943
[46]   Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination [J].
Wang, XS ;
Khuntirat, B ;
Qing, KY ;
Ponnazhagan, S ;
Kube, DM ;
Zhou, SZ ;
Dwarki, VJ ;
Srivastava, A .
JOURNAL OF VIROLOGY, 1998, 72 (07) :5472-5480
[47]   Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus [J].
Xiao, X ;
Li, J ;
Samulski, RJ .
JOURNAL OF VIROLOGY, 1998, 72 (03) :2224-2232
[48]   Recombinant adenovirus expressing adeno-associated virus cap and rep proteins supports production of high-titer recombinant adeno-associated virus [J].
Zhang, HG ;
Wang, YM ;
Xie, JF ;
Liang, X ;
Hsu, HC ;
Zhang, X ;
Douglas, J ;
Curiel, DT ;
Mountz, JD .
GENE THERAPY, 2001, 8 (09) :704-712
[49]   Production of recombinant adeno-associated virus vectors [J].
Zolotukhin, S .
HUMAN GENE THERAPY, 2005, 16 (05) :551-557
[50]   Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield [J].
Zolotukhin, S ;
Byrne, BJ ;
Mason, E ;
Zolotukhin, I ;
Potter, M ;
Chesnut, K ;
Summerford, C ;
Samulski, RJ ;
Muzyczka, N .
GENE THERAPY, 1999, 6 (06) :973-985